Cryoport, Inc. (CYRX) News
Follow Cryoport, Inc. (CYRX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 7 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Needham, KeyBanc Raise Cryoport Price Targets After Q3 Results
Needham maintained its Buy rating and raised its target to $28 from $19. KeyBanc maintained its Overweight rating and lifted its target to $20 from $17.
EQUITY | Nov 07, 2026, 02:03 PM UTC
L
Cryoport 3Q 2026: Revenue $50.22M, EPS ($0.25) — 10-Q Summary
Cryoport’s third-quarter revenue rose 13.5% year over year, while its net loss widened. Growth in Life Sciences Services and Products revenue was partly offset by higher costs; increased unrealized losses on short-term i
EARNINGS | Nov 05, 2026, 10:33 PM UTC
M
Cryoport Q3 Revenue Beats Estimates, Raises FY2026 Guidance
EQUITY | Nov 05, 2026, 09:52 PM UTC
M
Cryoport Raises 2026 Revenue Guidance to $197M–$199M
Cryoport reported Q3 2026 revenue of $50.2 million and adjusted EBITDA from continuing operations of $1.1 million. Commercial CGT revenue rose 20% year over year; the company did not provide its prior guidance range.
EARNINGS | Nov 05, 2026, 09:06 PM UTC
M
Cryoport Reports Third-Quarter 2026 Financial Results
Cryoport announced results for the third quarter and first nine months of 2026.
EQUITY | Nov 05, 2026, 09:05 PM UTC
L
Conference Call: CryoPort Affirms FY2026 Sales Guidance of $192.000M-$196.000M vs $194.390M Est
CryoPort (NASDAQ: CYRX ) affirms FY2026 sales outlook from $192.000 million-$196.000 million to $192.000 million-$196.000 million vs $194.390 million estimate.
EARNINGS | Aug 06, 2026, 10:21 PM UTC
L
CYRX Partners Verismo
Cryoport's IntegriCell cryopreservation services are selected by Verismo Therapeutics to support clinical KIR-CAR T cell therapy programs
EQUITY | Jun 25, 2026, 12:01 PM UTC